FDA Drug information
BIVALIRUDIN
Up to date, easily accessible information about drugs approved by the US Food & Drug Administration (FDA)
- Bivalirudin BIVALIRUDIN 250 mg/1 Civica, Inc.
- BIVALIRUDIN BIVALIRUDIN 250 mg/1 Eugia US LLC
- Bivalirudin BIVALIRUDIN 250 mg/1 Fresenius Kabi USA, LLC
- Bivalirudin BIVALIRUDIN 250 mg/1 Fresenius Kabi USA, LLC
- Bivalirudin BIVALIRUDIN 250 mg/1 Hainan Shuangcheng Pharmaceuticals Co., Ltd.
- Bivalirudin BIVALIRUDIN 250 mg/1 Hospira, Inc.
- Bivalirudin BIVALIRUDIN 250 mg/1 Par Pharmaceutical, Inc.
- Bivalirudin BIVALIRUDIN 250 mg/1 Sandoz Inc
- Bivalirudin BIVALIRUDIN 250 mg/1 Sandoz Inc
- Bivalirudin BIVALIRUDIN 250 mg/1 Slate Run Pharmaceuticals, LLC
- BIVALIRUDIN BIVALIRUDIN 250 mg/5mL Meitheal Pharmaceuticals Inc.
- Bivalirudin BIVALIRUDIN 250 mg/5mL Mylan Institutional LLC
Learning Zones
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.